AngioDynamics ( ANGO ) Reports Q1 Loss, Tops Revenue Estimates
AngioDynamics (ANGO) delivered earnings and revenue surprises of +28.57% and +4.75%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?
Here's How Much You Would Have Made Owning Edwards Lifesciences Stock In The Last 20 Years - Edwards Lifesciences ( NYSE:EW )
Edwards Lifesciences ( NYSE: EW ) has outperformed the market over the past 20 years by 7.57% on an annualized basis producing an average annual return of 16.53%. Currently, Edwards Lifesciences has a market capitalization of $45.32 billion.
EW Investor News: If You Have Suffered Losses in Edwards Lifesciences Corporation ( NYSE: EW ) , You Are Encouraged to Contact The Rosen Law Firm About Your Rights - Edwards Lifesciences ( NYSE:EW )
NEW YORK, Sept. 26, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation ( NYSE: EW ) .
SoCalBio Investor Conference Sessions to Spotlight Bioscience Workforce Development, Technology Transfer, and AI-Driven Innovation
LOS ANGELES, Sept. 25, 2025 ( GLOBE NEWSWIRE ) -- The Southern California Biomedical Council ( SoCalBio ) today announced the final lineup of expert panels for its 27th Annual Investor & Partnership Conference, taking place October 1-2 at the Hyatt Regency Newport Beach.
EDWARDS ( EW ) ALERT: Bragar Eagel & Squire, P.C. is Investigating Edwards Lifesciences Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Edwards Lifesciences ( NYSE:EW )
Bragar Eagel & Squire, P.C. Litigation Partners Encourage Investors Who Suffered Losses In Edwards ( EW ) To Contact Him Directly To Discuss Their Options
Picard Announces Appointment of Two New Members to its Board of Directors
Appointments strengthen Picard's Board with proven expertise in capital markets and global MedTech leadership Appointments strengthen Picard's Board with proven expertise in capital markets and global MedTech leadership ...
Here Are Billionaire Ken Griffin's 5 Biggest Stock Holdings
One was recently acquired by a much bigger company.
ABT vs. EW: Which Structural Heart Device Stock Is Worth Buying Now?
As the structural heart market expands, Abbott and Edwards battle for leadership. Which stock holds stronger growth momentum now?
Israel Englander's Millennium Goes All-In On Crypto And Healthcare While Rebalancing Big Tech Bets: Bitcoin ETF And Palantir Stakes Soar In Q2 - iShares Bitcoin Trust ( NASDAQ:IBIT ) , Palantir Technologies ( NASDAQ:PLTR )
Millennium Management LLC, led by billionaire Israel Englander, made bold moves in its portfolio according to its second-quarter 13F filings, significantly boosting exposure to cryptocurrency and healthcare while strategically rebalancing its big tech holdings.
Octane to Host Cardiovascular Tech Forum 2025 on September 11-12 in Newport Beach, California
NEWPORT BEACH, Calif., Aug. 26, 2025 ( GLOBE NEWSWIRE ) -- via InvestorWire -- Octane, an innovative organization building the SoCal of Tomorrow by connecting people, resources, and capital to fuel technology growth in Southern California, is pleased to announce that the Octane Cardiovascular ...
If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today - Edwards Lifesciences ( NYSE:EW )
Edwards Lifesciences EW has outperformed the market over the past 15 years by 2.56% on an annualized basis producing an average annual return of 15.33%. Currently, Edwards Lifesciences has a market capitalization of $47.73 billion.
Edwards Lifesciences Corporation Investors: Company Investigated by the Portnoy Law Firm - Edwards Lifesciences ( NYSE:EW )
Investors can contact the law firm at no cost to learn more about recovering their losses
Abbott Taps Growing TMVR Market With Tendyne System
ABT wins FDA nod for its Tendyne TMVR system, offering a minimally invasive option for patients with severe mitral valve disease.
EDWARDS ( EW ) ALERT: Bragar Eagel & Squire, P.C. is Investigating Edwards Lifesciences Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Edwards Lifesciences ( NYSE:EW )
Bragar Eagel & Squire, P.C. Litigation Partners Encourage Investors Who Suffered Losses In Edwards ( EW ) To Contact Him Directly To Discuss Their Options
Here Are Billionaire Ken Griffin's 5 Biggest Stock Holdings
A longtime leader in financial services tops the list.
Deal Dispatch: Performance Food Rejects Offer, Claire's Bankrupt - American Woodmark ( NASDAQ:AMWD ) , Boeing ( NYSE:BA )
Performance Food rejects offer; Bachan's, Hg and Yomeishu explore sales; Lufthansa drops Air Europa bid; NFL sells media to ESPN Skydance Media finally completed its $8-billion acquisition of Paramount Global. Sen. Warren called it a "wink, wink" arrangement.
Pediatrix Medical's Q2 Earnings Beat on Strong Patient Volumes
MD's Q2 earnings benefit from higher patient volumes and a declining expense level. It now projects 2025 adjusted EBITDA within $245-$255 million, up from the prior view of $220-$240 million.
FTC Sounds Alarm On Edwards' Heart Device, M&A Attempt - Edwards Lifesciences ( NYSE:EW )
FTC says Edwards' JenaValve deal would eliminate the only U.S. competition in TAVR-AR devices Despite FTC action, Edwards lifts 2025 adjusted EPS guidance to the high-end of $2.45-$2.55 per share. The market's back, and these 3 income stocks are thriving. See them here→
PROCEPT BioRobotics ( PRCT ) Earnings Transcript
Image source: The Motley Fool.Aug. 6, 2025, 8:30 p.m. ETChief Executive Officer - Reza ZadnoContinue reading ...
JenaValve Responds to FTC's Action Against Proposed Edwards Lifesciences Acquisition
IRVINE, Calif., Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- JenaValve Technology announced today that the U.S. Federal Trade Commission ( FTC ) moved to block the company's proposed acquisition by Edwards Lifesciences. JenaValve respectfully disagrees with the FTC's decision and remains committed ...
Edwards Lifesciences Stock: Likely To See Sluggish Price Action Through 2027 - Edwards Lifesciences ( NYSE:EW )
Edwards Lifesciences EW has just entered Phase 18, the final stage of its 18-phase Adhishthana cycle on the weekly chart. While the stock's setup doesn't necessarily point to a bearish outlook, the structure suggests that sluggish, range-bound price action could dominate through early 2027.
Edwards Lifesciences ( EW ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, July 24, 2025, at 5 p.m. ETNeed a quote from a Motley Fool analyst? Email [email protected] reading ...
ENSG's Q2 Earnings Beat on Higher Occupancy Rates, Stock Up 9%
Ensign Group's Q2 earnings improve 20.5% year over year, fueled by stronger occupancy, patient days and rental revenues.
Edwards Lifesciences Q2 Earnings - Edwards Lifesciences ( NYSE:EW )
Q2 sales hit $1.53 billion vs. $1.49 billion est., EPS at $0.67 vs. $0.62 est.; TAVR up 8.9%, TMTT up 61.9%. FY25 sales outlook raised to $5.90 billion-$6.10 billion; Goldman lifts price target to $101 on growth momentum. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On
US Stocks Hit New Highs As Magnificent Seven Reach $19 Trillion - AutoNation ( NYSE:AN )
Nvidia hits $4.25 trillion market cap; Magnificent Seven now worth $19 trillion combined. Bitcoin falls toward $115,800, on track for the second straight weekly loss for the first time since March 2025. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On
HCA Beats Q2 Earnings on Higher Admissions, Ups '25 EPS View
HCA Healthcare's Q2 earnings rose 24% year over year on stronger patient volumes. EPS for 2025 is expected to be within $25.5-$27, up from the earlier view of $24.05-$25.85.
Edwards Lifesciences Analysts Increase Their Forecasts After Stronger-Than-Expected Q2 Results - Edwards Lifesciences ( NYSE:EW )
Edwards Lifesciences Corporation EW reported better-than-expected second-quarter financial results on Thursday. Edwards Lifesciences posted adjusted earnings of 67 cents per share, beating market estimates of 62 cents per share. The company's quarterly sales came in at $1.532 billion versus ...
EW Stock Climbs on Q2 Earnings & Revenue Beat, Margins Down
Edwards Lifesciences posts a second-quarter 2025 earnings and revenue beat, with strong growth in TAVR and TMTT segments despite margin pressure.
PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO
SAN JOSE, Calif., July 24, 2025 ( GLOBE NEWSWIRE ) -- PROCEPT BioRobotics ( Nasdaq: PRCT ) ( "the Company" ) , a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that Larry L.
PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO - PROCEPT BioRobotics ( NASDAQ:PRCT )
Larry L. Wood to join PROCEPT BioRobotics effective September 2, 2025 Company confirms strong underlying business trends and pre-announces 2Q25 revenue of approximately $79.2 million, representing annual growth of 48%
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
There are no guarantees on Wall Street, especially when it comes to dividends. The board of directors of each company decides on the dividend in private. But income investors can glean some information from past dividend decisions, which is the only information available.
Robust TMTT Growth to Drive Edwards Lifesciences' Q2 Earnings
EW's Q2 earnings report is likely to benefit from soaring TMTT sales, with the segment expected to jump over 57% year over year.
Curious about Edwards Lifesciences ( EW ) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Should You Add Edwards Lifesciences Stock to Your Portfolio Now?
EW gains traction with surgical tech and TAVR growth, but macro pressures and FX headwinds weigh on margins.
Smart Money Going in Senior Health: Key Stocks in Elderly Care
RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.
How Do Investors Really Feel About Edwards Lifesciences? - Edwards Lifesciences ( NYSE:EW )
Edwards Lifesciences's EW short percent of float has risen 4.42% since its last report. The company recently reported that it has 6.07 million shares sold short, which is 1.18% of all regular shares that are available for trading.
BSX Raises 2025 Financial Outlook: What's Backing It?
Boston Scientific lifts its 2025 sales and EPS outlook after a strong Q1, with cardiology and EP segments fueling major gains.
ISRG's Minimally Invasive Ecosystem Powers Surgical Precision
ISRG's robotic platforms, led by da Vinci and Ion, are transforming surgical precision and driving strong stock gains.
Why Is Accuray ( ARAY ) Up 17% Since Last Earnings Report?
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock
EW's new late-breaking clinical data shows early intervention in AS may slash significant costs and improve patient outcomes.
Should Edwards Lifesciences Stock Remain in Your Portfolio Now?
EW stock is on investors' radars due to the promising structural heart opportunities and impressive TMTT portfolio.
What's Driving the Market Sentiment Around Edwards Lifesciences? - Edwards Lifesciences ( NYSE:EW )
Edwards Lifesciences's EW short percent of float has fallen 16.76% since its last report. The company recently reported that it has 7.93 million shares sold short, which is 1.54% of all regular shares that are available for trading.
P/E Ratio Insights for Edwards Lifesciences - Edwards Lifesciences ( NYSE:EW )
Looking into the current session, Edwards Lifesciences Inc. EW shares are trading at $75.58, after a 0.12% increase. Moreover, over the past month, the stock increased by 3.30%, but in the past year, decreased by 11.57%.
EMEA Growth & Product Launches to Support Boston Scientific Stock
Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.
Edwards Lifesciences Stock Earns Analyst Upgrade As Growth Outlook Brightens - Edwards Lifesciences ( NYSE:EW )
TMTT Q1 sales rose 58% YoY to $115 million, driven by global uptake of PASCAL and EVOQUE. Q1 adjusted EPS came in at $0.64, beating the $0.60 consensus and topping guidance midpoint. Today's manic market swings are creating the perfect setup for Matt's next volatility trade.
EW Q1 Earnings & Revenues Beat, Stock Climbs, '25 Sales View Raised
Edwards Lifesciences' first-quarter 2025 performance benefits from its differentiated portfolio of therapies to treat patients with structural heart disease.
Unlocking Q1 Potential of Edwards Lifesciences ( EW ) : Exploring Wall Street Estimates for Key Metrics
Evaluate the expected performance of Edwards Lifesciences (EW) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Is Edwards Lifesciences Gaining or Losing Market Support? - Edwards Lifesciences ( NYSE:EW )
Edwards Lifesciences's EW short percent of float has risen 14.2% since its last report. The company recently reported that it has 9.54 million shares sold short, which is 1.85% of all regular shares that are available for trading.
Solid TMTT Growth to Drive Edwards Lifesciences' Q1 Earnings
EW's first-quarter 2025 performance is likely to have gained from growth drivers across its businesses amid macroeconomic headwinds.
Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry - Boston Scientific ( NYSE:BSX ) , DexCom ( NASDAQ:DXCM )
Pharmaceuticals, which accounted for $200 billion in U.S. imports in 2024, are exempt from the 10% global tariff. Diabetes device makers face tariff-related pressures, while larger cardiac and orthopedic device firms are expected to adapt. With stocks plunging, steady income is key.
